Advancing next-gen treatments for obesity with greater data accessibility, collaboration, and compliance

Zealand Pharma A/S is a biotechnology company on a mission to change lives with next generation peptide medicines, focusing on metabolic diseases such as obesity. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand chose the Benchling R&D Cloud as its central source of truth for scientific data, collaboration, and insights. Teams across Zealand will use the Benchling R&D Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP. 

“Our research progresses quickly, every action needs to be traceable and verifiable. Scientists and partners can’t be slowed down by siloed systems or a lack of consistent data,” said Ludo Otterbein, Head of IT at Zealand Pharma. “Connecting the lab and automating data capture and sharing through technology is a critical priority. Benchling will provide Zealand with the digital data foundation that helps us safely and confidently scale new use cases and partners.”

The company works across many CMOs and partners and requires real-time access to data and secure, compliant information exchange. Zealand will deploy Benchling as a GxP-compliant platform for their development teams, including process development. With Benchling, Zealand scientists will benefit from increased control and visibility of data, fewer data transfer steps, and intuitive reporting and analytics, including native integrations with tools like JMP.